MISSISSAUGA, ON, Feb. 13 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM,
AIM: YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announced that its
wholly-owned US subsidiary, YM BioSciences USA Inc. ("YM-USA") has enrolled
the first patient in its Phase II trial investigating nimotuzumab in pediatric
patients with recurrent diffuse intrinsic pontine glioma (DIPG), a form of
inoperable, treatment-resistant brain cancer. The patient was treated at the
M.D Anderson Cancer Center under the care of Dr. Johannes Wolff. Nimotuzumab
is a humanized monoclonal antibody that targets the epidermal growth factor
receptor (EGFR).
